| abstract |
A method for inhibiting binding of alpha4beta1 integrin to its receptors, e.g. VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds, and the use of such compounds either as above or in preparations for the control or prevention of disease states in which alfa4beta1 is involved. |